Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI
JACC · 2026
DOI: 10.1016/j.jacc.2026.06.035 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2026. Verfasst von Miaohan Qiu und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaonin…. Hauptthemen laut MEDLINE: Peptide Fragments, Heparin, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In the BRIGHT-4 trial, among 6,016 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) with a radial artery approach, procedural anticoagulation with bivalirudin plus a post-PCI high-dose infusion for 2 to 4 hours reduced the 30-day primary composite outcome of all-cause death or Bleeding Academic Research Consortium (BARC) types 3 to 5 bleeding, as well as death and bleeding individually, compared with heparin monotherapy. OBJECTIVES: We sought to determine whether the benefits of bivalirudin apply principally to patients who are at low bleeding risk (LBR) as well as non-LBR. METHODS: In a prespecified analysis from BRIGHT-4, outcomes were examined by baseline bleeding risk, with LBR defined as a CRUSADE score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
- State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China; Air Force Medical University, Xi'an, Shaanxi, China.
- Department of Cardiology, Yueyang Central Hospital, Yueyang, Hunan, China.
- Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Cardiology, People's Hospital of Pingchang County, Pingchang, Sichuan, China.
- Department of Cardiology, Yunnan St John's Hospital, Kunming, Yunnan, China.
Zitieren
APA
Qiu, M., Duan, Y., Feng, X., Chen, K., Zhang, D., Zou, Y., Zheng, X., Zhao, G., Tian, N., Zheng, Z., Peng, X., Yang, Q., Liang, Z., Li, Y., Han, Y., & Stone, G. W. (2026). Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI. JACC. https://doi.org/10.1016/j.jacc.2026.06.035
Vancouver
Qiu M, Duan Y, Feng X, Chen K, Zhang D, Zou Y, et al. Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI. JACC. 2026. doi:10.1016/j.jacc.2026.06.035
BibTeX
@article{Qiu2026,
author = {Qiu, Miaohan and Duan, Yixuan and Feng, Xiaojian and Chen, Kui and Zhang, Dingbao and Zou, Yuncheng and Zheng, Xiaohui and Zhao, Gang and Tian, Nailiang and Zheng, Zeqi and Peng, Xiaoping and Yang, Qing and Liang, Zhenyang and Li, Yi and Han, Yaling and Stone, Gregg W},
title = {Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI},
journal = {JACC},
year = {2026},
doi = {10.1016/j.jacc.2026.06.035}
}
EUVIMED